Natixis’s Replimune Group REPL Stock Holding History

Natixis’s Portfolio REPL Stock Details REPL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-19,200	Closed	-$520K	–	1299
2021 Q4	$520K	Buy	+19,200	New	+$574K	﹤0.01%	1025

Other funds holding REPL

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

OFM

Omega Fund Management Boston, Massachusetts $163M AUM 107.06% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

AVLSA

Atlas Venture Life Science Advisors Cambridge, Massachusetts $790M AUM 223.66% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Emerald Advisers Leola, Pennsylvania $3.16B AUM 109.58% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Natixis's REPL Position: Q1 2022 in Review

Natixis sold out of Replimune Group (REPL) in Q1 2022, closing a stake of 19,200 shares — an estimated $520K sold.

Natixis first reported a position in REPL in Q4 2021 and held it in 1 quarter. The position peaked at $520K in Q4 2021. 107 funds tracked by Wall St. Rank hold REPL as of Q1 2022.

Natixis reported no remaining Replimune Group position as of Q1 2022 after selling out during the quarter.
Natixis sold 19,200 Replimune Group shares in Q1 2022, an estimated $520K.
Natixis first reported a position in Replimune Group in Q4 2021 and held it in 1 quarter.
Natixis's Replimune Group position peaked at $520K in Q4 2021.
107 funds tracked by Wall St. Rank held Replimune Group as of Q1 2022.

Based on Natixis's 13F filing for Q1 2022, filed 13 May 2022.